Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
This is a single-center, open-label, phase I study to assess the safety and efficacy of the oral chemotherapy capecitabine in combination with cemiplimab in patients with hormone-receptor-positive (HR+) metastatic breast cancer.
Hormone Receptor-positive Breast Cancer
DRUG: Cemiplimab|DRUG: Capecitabine
Recommended Phase 2 Dose (RP2D), Recommended Phase 2 dose of Capecitabine combined with Cemiplimab will be determined by testing 2 dose levels. RP2D reflects the highest dose that did not cause Dose Limiting Toxicity (DLT), Up to 24 months
Objective Response Rate (ORR), Objective response rate is defined as the sum of complete response and partial response based on Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1., Up to 24 months|Clinical Benefit Rate (CBR), Clinical benefit rate is defined as the sum of complete response, partial response, and stable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1., Up to 24 months|Progression Free Survival (PFS), Progression free survival is defined as the time from start of treatment to documented disease progression or death due to any cause, Up to 24 months
This is a single-center, open-label, phase I study to assess the safety and efficacy of the oral chemotherapy capecitabine in combination with cemiplimab in patients with hormone-receptor-positive (HR+) metastatic breast cancer.